Analysts Anticipate Synlogic Inc (SYBX) Will Post Quarterly Sales of $200,000.00

Equities research analysts expect Synlogic Inc (NASDAQ:SYBX) to post sales of $200,000.00 for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Synlogic’s earnings, with the lowest sales estimate coming in at $100,000.00 and the highest estimate coming in at $300,000.00. Synlogic posted sales of $110,000.00 during the same quarter last year, which would indicate a positive year over year growth rate of 81.8%. The business is scheduled to report its next earnings report on Tuesday, March 19th.

According to Zacks, analysts expect that Synlogic will report full year sales of $2.33 million for the current year, with estimates ranging from $1.31 million to $2.70 million. For the next year, analysts expect that the business will post sales of $1.01 million, with estimates ranging from $400,000.00 to $2.00 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that follow Synlogic.

Synlogic (NASDAQ:SYBX) last announced its quarterly earnings results on Tuesday, November 13th. The biotechnology company reported ($0.43) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.21. The firm had revenue of $1.80 million for the quarter, compared to the consensus estimate of $0.20 million. Synlogic had a negative return on equity of 39.07% and a negative net margin of 1,912.74%.

SYBX has been the topic of several research reports. Citigroup upped their target price on Synlogic to $26.00 and gave the company a “buy” rating in a research report on Wednesday, September 5th. Zacks Investment Research downgraded Synlogic from a “buy” rating to a “hold” rating in a research report on Wednesday, August 15th. Wedbush reaffirmed an “outperform” rating on shares of Synlogic in a research report on Friday, September 7th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Synlogic in a research report on Tuesday, November 13th. Finally, Oppenheimer set a $18.00 target price on Synlogic and gave the company a “buy” rating in a research report on Monday, November 12th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Synlogic has a consensus rating of “Buy” and an average target price of $18.11.

NASDAQ SYBX traded up $0.01 during trading on Thursday, reaching $8.75. 168,706 shares of the company’s stock were exchanged, compared to its average volume of 120,249. Synlogic has a fifty-two week low of $7.20 and a fifty-two week high of $15.00. The company has a market cap of $222.41 million, a PE ratio of -1.49 and a beta of 2.62.

In other news, insider Paul Francis Miller sold 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 18th. The stock was sold at an average price of $13.05, for a total value of $39,150.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders sold 12,000 shares of company stock worth $135,390 in the last ninety days. 23.30% of the stock is owned by company insiders.

Large investors have recently modified their holdings of the stock. Dimensional Fund Advisors LP acquired a new stake in Synlogic during the first quarter worth approximately $538,000. Artal Group S.A. acquired a new stake in Synlogic during the third quarter worth approximately $2,842,000. NF Trinity Capital Hong Kong Ltd acquired a new stake in Synlogic during the third quarter worth approximately $975,000. Northern Trust Corp acquired a new stake in Synlogic during the first quarter worth approximately $249,000. Finally, Wells Fargo & Company MN acquired a new stake in Synlogic during the third quarter worth approximately $351,000. 80.90% of the stock is currently owned by institutional investors and hedge funds.

About Synlogic

Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy, which is in Phase I clinical trial for the treatment of patients with liver disease and hepatic encephalopathy, and urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.

Read More: How to Profit and Limit Losses With Stop Orders

Get a free copy of the Zacks research report on Synlogic (SYBX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Synlogic (NASDAQ:SYBX)

Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply